Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anh Ngo

Interventional Pain Medicine Newington, NH Medical Doctor

NPI 1609076066 CMS profile 636565

101 Shattuck Way Ste 6, Newington, NH 03801

Open in the dashboard

General payments

$39,455

642 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anh Ngo of Newington, NH is reported in the CMS Open Payments database as having received $39,455 across 642 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,088 116
2024 General $2,817 84
2023 General $4,271 123
2022 General $3,884 90
2021 General $9,382 82
2020 General $5,296 65
2019 General $9,716 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anh Ngo
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Anh Ngo were reported at $4,088. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Anh Ngo Interventional Pain Medicine median Middle half National median
2019 $9,716 $684 $216–$2,079 $163
2020 $5,296 $382 $122–$1,109 $114
2021 $9,382 $552 $167–$1,554 $132
2022 $3,884 $605 $187–$1,924 $149
2023 $4,271 $671 $195–$1,915 $160
2024 $2,817 $684 $206–$1,837 $164
2025 $4,088 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $21,186 214 payments
  2. Relievant Medsystems, Inc. $2,142 16 payments
  3. AbbVie, Inc. $1,960 83 payments
  4. Medtronic Vascular, Inc. $1,844 11 payments
  5. Janssen Pharmaceuticals, Inc $1,279 17 payments
  6. Medtronic USA, Inc. $1,241 14 payments
  7. Nevro Corp. $1,193 15 payments
  8. Vertos Medical, Inc. $989 15 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $948 66 payments
  10. SPR Therapeutics, Inc $884 4 payments
  11. Other $5,790 187 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $22,251 596 payments
  2. Travel and Lodging $11,590 43 payments
  3. Consulting Fee $5,600 1 payment
  4. Entertainment $13 1 payment
  5. Education $1 1 payment
Products named General payments · program years 2019–2025
  1. GENERAL PAIN MANAGEMENT $6,550 31 payments
  2. SPECTRA WAVEWRITER $5,489 39 payments
  3. Intracept Pain $1,469 13 payments
  4. Intracept Pain $1,315 12 payments
  5. Intracept Pain $1,315 12 payments
  6. Intracept Pain $1,315 12 payments
  7. SPRAVATO $1,279 17 payments
  8. General - Pain Management $1,275 32 payments
  9. General Therapies $1,248 7 payments
  10. SUPERION $1,195 8 payments
  11. Other $20,877 557 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

399

Median for Pain Management: 951

Drug cost

$10,120

Median for Pain Management: $26,034

Branded share of claims

0%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lidocaine Generic 19 $2,775
Tizanidine Hcl Generic 155 $2,089
Naloxone Hcl Generic 34 $1,714
Gabapentin Generic 77 $1,606
Diclofenac Sodium Generic 11 $515
Diclofenac Potassium Generic 18 $465
Oxycodone Hcl Generic 17 $247
Pregabalin Generic 18 $225
Cyclobenzaprine Hcl Generic 15 $177
Meloxicam Generic 13 $167

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$848,815

Of which drugs: $10,338

Medicare patients

340

Average age 71

Services billed

33,758

220 women, 120 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 68%
Depression 44%
Chronic kidney disease 25%
Diabetes 24%
Ischemic heart disease 23%
COPD 21%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 25 78 $7,303
Injection, methylprednisolone acetate, 1 mg J1010 Office 128 17,880 $1,813
Injection, methylprednisolone acetate, 80 mg J1040 Office 61 85 $635
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 125 3,719 $334
Injection, ketorolac tromethamine, per 15 mg J1885 Office 29 76 $42

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SPRAVATO
  • Janssen Pharmaceuticals, Inc $205
$205 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $197
$197 — —
UBRELVY
  • AbbVie, Inc. $160
$160 — —
BOTOX
  • AbbVie, Inc. $147
$147 — —
QULIPTA
  • AbbVie, Inc. $134
$134 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

642 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in New Hampshire

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record